SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 13th, 2025 • Quince Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 12, 2025, by and among Quince Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 6th, 2025 • TuHURA Biosciences, Inc./Nv • Pharmaceutical preparations • Nevada
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 2, 2025, by and among TuHURA Biosciences, Inc., a Nevada corporation (the “Company”), and each of the entities executing signature pages to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 25th, 2025 • Verastem, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 25, 2025, by and among Verastem, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 6th, 2025 • Tenax Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 4, 2025, by and among Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 10th, 2025 • Grace Therapeutics, Inc. • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 10th, 2025 • Grace Therapeutics, Inc. • Pharmaceutical preparations • Delaware
FORM OF SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 3rd, 2025 • Tectonic Therapeutic, Inc. • Biological products, (no disgnostic substances) • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of February 3, 2025, by and among Tectonic Therapeutic, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 27th, 2025 • Inogen Inc • Orthopedic, prosthetic & surgical appliances & supplies • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of January 25, 2025, by and between Inogen, Inc., a Delaware corporation (the “Company”), and Yuwell (Hong Kong) Holdings Limited, a company established under the laws of Hong Kong (together with its permitted assigns, the “Investor”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 8th, 2025 • AtlasClear Holdings, Inc. • Finance services • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 27th, 2024 • Vor Biopharma Inc. • Biological products, (no disgnostic substances) • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 26, 2024, by and among Vor Biopharma Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 23rd, 2024 • RAPT Therapeutics, Inc. • Pharmaceutical preparations • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 2nd, 2024 • Senti Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 26th, 2024 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
The undersigned (the “Holder”) hereby requests that the federal securities law restrictive legend be removed from the book entries representing _________ of shares of common stock, par value $0.0001 per share (the “Shares”), of Cidara Therapeutics, Inc. (the “Company”). In connection with the legend removal, Holder hereby represents to, and agrees with, you as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 18th, 2024 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 18, 2024, by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 4th, 2024 • KalVista Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2024, by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 4th, 2024 • Neurogene Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2024, by and among Neurogene Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENT2Securities Purchase Agreement • October 20th, 2024
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [ ], 20[ ], by and among [ ], a [type of entity] [incorporated/organized] under the laws of [jurisdiction of incorporation/organization] (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 10th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 12th, 2024 • Summit Therapeutics Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of September 11, 2024, by and among Summit Therapeutics Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 6th, 2024 • Tenax Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 6, 2024, by and among Tenax Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 30th, 2024 • Day One Biopharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 30, 2024, by and among Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 3rd, 2024 • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [ ], 20[ ], by and among [ ], a [Delaware corporation] (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 13th, 2024 • Replimune Group, Inc. • Biological products, (no disgnostic substances) • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 3rd, 2024 • Summit Therapeutics Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 3, 2024, by and among Summit Therapeutics Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 28th, 2024 • Xilio Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of March 28, 2024 (the “Execution Date”) by and among Xilio Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”).